Researchers at The University of Texas at Austin, including Texas ChE’s Dr. George Georgiou and Dr. Jennifer Maynard, successfully culminated years of work when a drug they engineered for the treatment and prevention of inhalational anthrax — the anthrax antitoxin obiltoxaximab — received approval March 21 from the U.S. Food and Drug Administration (FDA). Part … Read the rest »